A Phase I Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14c]-Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors

Investigational New Drugs - Netherlands
doi 10.1007/s10637-017-0509-1

Related search